If you have robotic prostate surgery, your risk of recurrence depends on your cancer stage, grade, PSA level and surgical findings. There is no single recurrence rate that applies to everyone.
Your PSA should fall to a very low or undetectable level after surgery. Published recurrence estimates vary considerably between studies. Some robotic prostatectomy cohorts report biochemical recurrence in around 13–20% by five years, while longer-term studies report higher cumulative rates as follow-up increases. Your individual risk may be substantially higher or lower depending on your cancer and postoperative findings.
What Does Prostate Cancer Recurrence Mean After Surgery?
After radical prostatectomy, your PSA is expected to fall to an undetectable level. A commonly used definition of biochemical recurrence is a PSA of 0.2 ng/mL or higher confirmed by a subsequent test. However, specialists also consider the pattern and speed of PSA rise, and current European guidance does not use a single PSA threshold as the only measure of clinically meaningful recurrence.
Biochemical recurrence can happen before you have any symptoms and does not automatically mean the cancer has spread. Your specialist will assess your PSA pattern and other risk factors to decide whether you need further tests or treatment.
What Do Published Robotic Surgery Recurrence Rates Show?
Long-term robotic prostatectomy studies generally show good cancer control, although recurrence becomes more common as the follow-up period increases. The table below provides examples from several major robotic prostatectomy cohorts, but you should not treat these studies as though they describe one group of patients because they included different cancer risk profiles and were carried out at different centres.
| Study/cohort | Follow-up | Published biochemical outcome |
| 1,384-patient RARP cohort | 1 year | 95.1% BCR-free survival |
| Same cohort | 3 years | 90.6% BCR-free survival |
| Same cohort | 5 years | 86.6% BCR-free survival |
| Same cohort | 7 years | 81.0% BCR-free survival |
| 483-patient long-term RARP cohort | 10 years | 73.1% BCR-free survival |
| 885-patient European RARP cohort | Median 10.5 years | 81.8% BCR-free survival |
| 1,807-patient long-term RALP cohort | 15 years | 28.1% biochemical failure |
How Is Your PSA Monitored in the UK After Prostatectomy?
After prostatectomy, your PSA is checked regularly to look for early signs of recurrence. NICE recommends your first test no earlier than six weeks after treatment, followed by testing at least every six months for the first two years and annually thereafter.
Your PSA should usually fall to a very low or undetectable level after surgery. Even if your early results are reassuring, you should continue long-term monitoring because recurrence can occasionally occur many years later.
Is Persistent PSA the Same as Cancer Recurrence?
Persistent PSA means that PSA remains detectable after surgery rather than first becoming undetectable and rising later. Current EAU guidance notes that most studies define PSA persistence as a level of 0.1 ng/mL or higher within approximately four to eight weeks after radical prostatectomy.
Persistent PSA is reported in around 5–20% of patients. Possible explanations include persistent local disease, pre-existing metastatic disease or residual benign prostate tissue, so the result needs to be interpreted alongside its timing, subsequent PSA measurements and your pathology.
When Does Biochemical Recurrence Usually Happen?
If you develop biochemical recurrence after robotic prostatectomy, it often occurs within the first few years. In the 1,384-patient RARP cohort, the median time to biochemical recurrence among men who recurred was 20.4 months. About 65% of recurrences occurred within three years and 86.2% within five years.
However, recurrence can happen much later, even after several years of an undetectable PSA. Your specialist will consider when your PSA starts rising and how quickly it changes when assessing your individual risk.
How Much Does the Pathological Stage Affect Recurrence?
Your pathological stage is one of the strongest predictors of whether your PSA may return after prostatectomy. It is determined by examining the prostate after surgery and can give you more accurate information than the clinical stage estimated before treatment. A robotic prostatectomy study with more than five years of follow-up also found clear differences in five-year biochemical recurrence-free survival depending on pathological stage.
| Pathological stage | 5-year biochemical recurrence-free survival | Approximate recurrence by 5 years |
| pT2 | 89.8% | 10.2% |
| pT3a | 66.2% | 33.8% |
| pT3b | 39.3% | 60.7% |
In this study, about nine in ten men with pT2 disease remained free from biochemical recurrence at five years, compared with approximately two-thirds of those with pT3a disease and four in ten with pT3b disease. Other robotic cohorts report different percentages but show the same overall pattern: recurrence risk increases as pathological disease extent becomes greater.
How Does Prostate Cancer Grade Affect Recurrence?
Your Grade Group or Gleason score is an important predictor of recurrence because it reflects how aggressive the cancer appears under the microscope. Importantly, Gleason 3+4 and 4+3 are both Gleason score 7 but do not carry the same prognosis.
| Pathological Gleason score | 5-year biochemical recurrence-free survival |
| 3+3 or lower | 97% |
| 3+4 | 86% |
| 4+3 | 62% |
| 4+4 or higher | 43% |
The same Gleason score of seven can therefore have different outcomes depending on which pattern is dominant, which is why your consultant will consider your full pathology report rather than simply describing your cancer as “Gleason 7”. Higher Grade Groups generally indicate a greater risk of recurrence and spread, but you should consider your grade alongside your stage, surgical margins, lymph nodes and PSA, as a higher grade does not mean recurrence is inevitable and a lower grade does not remove the risk completely.
How Does Your Pre-Operative Risk Group Change the Long-Term Figures?
One particularly informative long-term robotic study followed 1,807 men for a median of 14.1 years and reported results according to their D’Amico risk group before surgery.
The differences were considerable.
| Pre-operative risk group | 15-year biochemical failure | 15-year metastasis | 15-year prostate cancer-specific mortality |
| Low risk | 15.2% | 1.1% | 0.5% |
| Intermediate risk | 38.3% | 4.1% | 3.4% |
| High risk | 44.1% | 13.0% | 6.6% |
How Much Do Positive Surgical Margins Affect Recurrence?
A positive surgical margin means cancer cells are found at the edge of the tissue removed during your prostatectomy. It can increase your risk of biochemical recurrence, but it does not mean that recurrence is certain.
Your specialist will consider a positive surgical margin alongside your cancer grade, pathological stage and postoperative PSA results when estimating your individual recurrence risk.
Why Do Seminal Vesicle and Lymph-Node Findings Matter?
If prostate cancer has reached your seminal vesicles or lymph nodes, your risk of recurrence is generally higher because the cancer has extended beyond the prostate. Your pathology report can therefore provide important information about how likely surgery alone is to control the cancer long term.
If cancer is found in your lymph nodes, you may need closer PSA monitoring or additional treatment such as radiotherapy or hormone therapy. Your specialist will consider the number of affected nodes, cancer grade, surgical margins and postoperative PSA when planning your next steps.
Why Is PSA Doubling Time Important After Recurrence?
Your PSA level matters, but how quickly it rises can provide important information about your recurrence risk. PSA doubling time estimates how long your PSA takes to double, with a faster rise generally linked to a greater risk of progression than a slower increase. NICE recommends estimating PSA doubling time after biochemical relapse using at least three PSA measurements taken over six months or more, while European guidelines use PSA doubling time alongside your pathological Grade Group to classify recurrence as lower or higher risk.
| EAU risk category after radical prostatectomy | Definition |
| EAU low-risk BCR | PSA doubling time over 1 year AND pathological ISUP Grade Group below 4 |
| EAU high-risk BCR | PSA doubling time 1 year or less OR pathological ISUP Grade Group 4–5 |
This risk approach recognises that two men with the same PSA level can have very different outlooks, as a small, slowly rising PSA years after surgery may behave differently from a rapidly doubling PSA soon after treatment in someone with Grade Group 5 cancer. Your medical team therefore looks at the PSA trend over time rather than reacting to a single result.
Does Biochemical Recurrence Mean the Cancer Will Become Metastatic?
Not necessarily, and this is an important distinction when you look at your recurrence risk. One 15-year robotic prostatectomy study reported a 28.1% biochemical failure rate, compared with 4.0% metastatic progression and 2.5% prostate cancer-specific mortality, while another ten-year study reported 73.1% biochemical recurrence-free survival but 97.5% metastasis-free survival and 98.8% prostate cancer-specific survival. These figures show that PSA recurrence is much more common than metastatic progression or death from prostate cancer.
| Long-term robotic outcome in one 10-year cohort | Rate |
| Biochemical recurrence-free survival | 73.1% |
| Metastasis-free survival | 97.5% |
| Prostate cancer-specific survival | 98.8% |
This large gap exists partly because PSA is highly sensitive and can detect recurrence long before there is enough cancer to cause symptoms or visible metastatic disease. Treatment after recurrence may also prevent or delay further progression, which is why current EAU guidance emphasises that a measurable or rising PSA does not inevitably mean your cancer will become clinically apparent or metastatic.
When Might You Need a PSMA PET/CT Scan?
If your PSA starts rising after robotic prostatectomy, your specialist may recommend a PSMA PET/CT scan to look for recurrent prostate cancer. Current EAU guidance gives a weak recommendation to perform PSMA PET/CT after prostatectomy when PSA is above 0.2 ng/mL if the result is likely to influence subsequent treatment decisions.
The scan may identify cancer in the prostate bed, lymph nodes or elsewhere in your body. However, a negative result at a very low PSA does not always rule out microscopic cancer, so your specialist will also consider your PSA pattern, doubling time and pathology.
What Happens If Your PSA Starts Rising?
A rising PSA after prostate surgery does not automatically mean your cancer has spread. Your specialist will assess the pattern before deciding what happens next.
- PSA trend: Several PSA results may be reviewed to see how quickly the level is rising.
- Further imaging: A PSMA PET/CT may be considered if it could help locate recurrent cancer.
- Salvage radiotherapy: Radiotherapy to the prostate bed may be considered or offered after biochemical recurrence when there are no known distant metastases, depending on your PSA pattern, pathology and individual treatment plan.
- Additional treatment: Hormone therapy may be combined with salvage treatment in selected patients based on recurrence risk, pathology and specialist assessment.
Your treatment will depend on your PSA pattern, pathology and scan results. Your specialist can explain which option is most appropriate for you.
Does Robotic Surgery Itself Reduce the Risk of Recurrence?
Some comparative studies and an older meta-analysis have reported higher five-year biochemical recurrence-free survival after robot-assisted prostatectomy than after open surgery. However, surgical approach is closely linked with patient selection, surgeon experience, centre volume and treatment era, and current evidence does not show that robotic technology itself guarantees a lower long-term recurrence risk.
Your cancer biology, pathological stage, Grade Group, margins, lymph-node findings and postoperative PSA remain central to estimating recurrence risk.
Myth vs Fact
| Myth | Fact |
| Robotic prostatectomy has one standard recurrence rate. | No. Recurrence risk varies greatly according to stage, Grade Group, PSA and postoperative pathology. |
| Any detectable PSA means the cancer has definitely spread. | No. Biochemical recurrence can occur years before metastatic disease becomes detectable. |
| A positive margin means recurrence is inevitable. | No. Positive margins increase recurrence risk, but many men with a positive margin do not develop biochemical recurrence. |
| A PSA of 0.2 ng/mL is the only level that matters. | No. It is a commonly used BCR definition, but guidelines also consider PSA trends and specialists may consider early salvage treatment before a higher PSA threshold is reached. |
| Biochemical recurrence means metastatic prostate cancer. | No. Long-term RARP studies show biochemical recurrence is considerably more common than metastatic progression. |
| Robotic technology guarantees the cancer will not return. | No. Cancer characteristics and surgical/pathological findings remain the major determinants of recurrence risk. |
How Can Your Personal Recurrence Risk Be Estimated?
Your personal recurrence risk can be estimated using your PSA, Grade Group, MRI findings and cancer stage before surgery. After prostatectomy, your pathology report provides further information, including your final Grade Group, surgical margins, seminal vesicle and lymph-node findings.
Your first postoperative PSA is also important. If it becomes undetectable, this is reassuring, while persistent or rising PSA may require closer assessment. When discussing specialist robotic prostate surgery, ask how your own pathology and PSA results affect your risk rather than relying only on an average recurrence percentage.
Key Takeaways
- There is no single recurrence rate after robotic prostatectomy because cancer risk varies significantly between patients.
- Five-year biochemical recurrence estimates vary between studies; individual RARP cohorts report rates around 13–19%, while a long-term meta-analysis estimated approximately 20% based on pooled five-year BCR-free survival.
- A commonly used definition of biochemical recurrence is a confirmed postoperative PSA of approximately 0.2 ng/mL or higher, but PSA trends and clinical context are also important.
- Pathological stage, Grade Group, pre-operative PSA, surgical margins and lymph-node or seminal-vesicle involvement are important predictors of recurrence.
- PSA doubling time helps distinguish lower- and higher-risk biochemical recurrence.
- Biochemical recurrence does not automatically mean metastatic cancer; 15-year RARP data show biochemical failure is much more common than metastatic progression or prostate-cancer-specific death.
- NICE recommends long-term PSA monitoring after radical treatment, while suitable patients with biochemical relapse and no known metastases may be offered salvage radiotherapy.
- PSMA PET/CT may help localise recurrent disease when PSA rises and the result would change treatment planning.
Frequently Asked Questions
1. What Is the Recurrence Rate After Robotic Prostate Surgery?
Recurrence rates vary depending on your cancer’s stage, grade and pathology. Some robotic prostatectomy cohorts report biochemical recurrence in around 13–19% by five years. Longer-term studies report higher cumulative rates, including approximately 18–27% at around ten years and around 28% at 15 years.
2. When Does Prostate Cancer Usually Recur After Robotic Surgery?
Many recurrences occur within the first few years after surgery, although recurrence can happen much later. Regular PSA monitoring helps detect changes early, even when your initial results are reassuring.
3. Does Cancer Stage Affect Recurrence Risk?
Yes. Cancer that remains confined to the prostate generally has a lower recurrence risk than cancer that has extended outside the prostate or into the seminal vesicles.
4. Does Gleason Score Affect Recurrence?
Yes. A higher Gleason score or Grade Group generally indicates more aggressive cancer and a greater likelihood of recurrence. Your specialist will consider your grade alongside other pathology results.
5. Do Positive Surgical Margins Increase Recurrence Risk?
Yes. A positive surgical margin can increase your risk of biochemical recurrence because cancer cells are found at the edge of the removed prostate tissue. Your specialist will interpret the margin finding alongside your pathological stage, Grade Group and postoperative PSA.
6. Does a Rising PSA Mean the Cancer Has Spread?
Not necessarily. A rising PSA can indicate biochemical recurrence without visible metastatic disease, and further treatment may be able to control the cancer.
7. What Is PSA Doubling Time?
PSA doubling time measures how quickly your PSA increases after surgery. A shorter doubling time can indicate a higher-risk recurrence, so your specialist may assess several PSA results over time.
8. Can Prostate Cancer Recurrence Be Treated After Robotic Surgery?
Yes. Depending on your PSA, pathology and scan results, treatments such as salvage radiotherapy and hormone therapy may be considered to control recurrent disease.
9. Can a PSMA PET/CT Detect Recurrent Prostate Cancer?
A PSMA PET/CT can sometimes identify small areas of recurrent prostate cancer that conventional scans may not detect. Your specialist may recommend it when the result could help guide further treatment.
10. How Can I Find Out My Personal Recurrence Risk?
Your individual risk can be estimated using your postoperative PSA, Grade Group, pathological stage, surgical margins and lymph-node findings. Your specialist can combine these factors to provide a more personalised assessment.
Final Thoughts: What Can You Expect After Robotic Prostate Surgery?
The risk of prostate cancer recurrence after robotic surgery varies considerably between individuals. Your PSA pattern, Grade Group, pathological stage, surgical margins and lymph-node findings are more useful for estimating your personal risk than a general recurrence percentage.
If you are considering robotic prostate surgery in London and would like specialist advice, you can contact us to discuss your options and arrange a consultation tailored to your individual needs.
References:
- Menon, M. et al. (2010) ‘Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up’, European Urology, 58(6), pp. 838–846. Available at: https://pubmed.ncbi.nlm.nih.gov/20869162/
- Diaz, M. et al. (2015) ‘Oncologic outcomes at 10 years following robotic radical prostatectomy’, European Urology, 67(6), pp. 1168–1176. Available at: https://pubmed.ncbi.nlm.nih.gov/24996687/
- Rajan, P. et al. (2018) ‘Oncologic outcomes after robot-assisted radical prostatectomy: a large European single-centre cohort with median 10-year follow-up’, European Urology Focus, 4(3), pp. 351–359. Available at: https://pubmed.ncbi.nlm.nih.gov/28753802/
- Sood, A. et al. (2023) ‘15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer’, Prostate Cancer and Prostatic Diseases, 26(4), pp. 778–786. Available at: https://pubmed.ncbi.nlm.nih.gov/37142635/
- Kim, K.H. et al. (2013) ‘Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years’, Asian Journal of Andrology, 15(3), pp. 404–408. Available at: https://pubmed.ncbi.nlm.nih.gov/23524532/
- Wang, L. et al. (2017) ‘Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis’, International Urology and Nephrology, 49(6), pp. 995–1005. Available at: https://pubmed.ncbi.nlm.nih.gov/28238148/
- National Institute for Health and Care Excellence (2019, updated 2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- European Association of Urology (2026) EAU Guidelines on Prostate Cancer. EAU Guidelines Office, Arnhem, The Netherlands. Available at: https://uroweb.org/guidelines/prostate-cancer
- Liss, M.A. et al. (2012) ‘Robot-assisted radical prostatectomy: 5-year oncological and biochemical outcomes’, The Journal of Urology, 188(6), pp. 2205–2210. Available at: https://pubmed.ncbi.nlm.nih.gov/23083657/